<?xml version="1.0" encoding="UTF-8"?><oembed><type>video</type><version>1.0</version><html>&lt;iframe src=&quot;https://www.loom.com/embed/87ad52cb33894aee8ba51df63ae98815&quot; frameborder=&quot;0&quot; width=&quot;1184&quot; height=&quot;888&quot; webkitallowfullscreen mozallowfullscreen allowfullscreen&gt;&lt;/iframe&gt;</html><height>888</height><width>1184</width><provider_name>Loom</provider_name><provider_url>https://www.loom.com</provider_url><thumbnail_height>888</thumbnail_height><thumbnail_width>1184</thumbnail_width><thumbnail_url>https://cdn.loom.com/sessions/thumbnails/87ad52cb33894aee8ba51df63ae98815-a47973170b949d27.gif</thumbnail_url><duration>716.907</duration><title>Biologics Below the Knee </title><description>Dr. Martin explains myths and clarifies how biologics like PRP and Wharton’s Jelly should be understood, especially for cartilage based injuries. He distinguishes autologous versus allogeneic human cell and tissue products and says these are not drugs, noting that no human cell and tissue product is FDA approved to diagnose, treat, cure, or prevent disease, including PRP or BMAC. Using examples like partial Achilles tears, the talk argues that stem cell and growth factor claims can mislead patients, because PRP mainly supports type one collagen differentiation and may not provide complete cartilage building blocks. He contrasts this with tissue specific allografts, emphasizing that Wharton’s Jelly contains type one collagen, type three collagen, and hyaluronic acid, and is framed as a more comprehensive approach.</description></oembed>